文献速递炎症性肠病

克罗恩病患者人工甜味剂与乳化剂定量及其与疾病活动度的关系:ENIGMA研究

Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach.
PubMed 文献 · Gut · 2026-08-06

ENIGMA研究分析了来自澳大利亚、香港和中国大陆的487名受试者(245例CD患者和242例对照)的1461份生物样本,检测粪便、尿液和血清中阿斯巴甜、三氯蔗糖、糖精和P-80水平。CD患者甜味剂水平高于对照(均p<0.0001),P-80在CD中主要经水解降解,其代谢物与疾病活动度相关,基于甜味剂和P-80代谢物的模型区分活动期与缓解期CD的AUC在发现队列为0.86,两个验证队列平均0.94。

要点

  • CD患者甜味剂水平显著高于对照,所有队列均p<0.0001。
  • CD中P-80主要经水解降解,其代谢物增加肠道通透性并促进甜味剂转运。
  • 甜味剂和P-80代谢物模型可区分活动期与缓解期CD,验证队列平均AUC为0.94。

核心结论

  • 首次在人体中证实CD患者P-80代谢与对照不同,甜味剂和P-80代谢物与疾病活动度显著相关,可能作为无创生物标志物。

研究设计与样本

  • 多中心病例对照研究,纳入澳大利亚、香港和中国大陆487名受试者(245例CD和242例对照),分析1461份粪便、尿液和血清样本。
  • 检测阿斯巴甜、三氯蔗糖、糖精和P-80水平,用克罗恩病活动指数和粪钙卫蛋白评估CD活动度。
  • 采用广义线性模型(GLM)基于P-80和甜味剂区分活动期与缓解期CD。

主要发现

  • CD患者甜味剂水平高于对照,所有队列均p<0.0001。
  • P-80在CD中主要经水解降解,在对照中主要经氧化还原降解,其原形未检出。
  • CD相关P-80代谢物与患者尿甜味剂正相关,体外增加肠道通透性,促进甜味剂跨上皮转运。
  • 活动期CD中甜味剂和特定CD相关P-80代谢物水平更高。
  • GLM模型区分活动期与缓解期CD的AUC在发现队列为0.86,两个独立验证队列(澳大利亚和中国大陆)平均AUC为0.94。

临床怎么用

  • 甜味剂和P-80代谢物可能作为评估CD活动度的无创生物标志物,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Food additives have been linked to increased Crohn's disease (CD) risk and activity, but their human quantification has not been explored. OBJECTIVE: We aimed to measure artificial sweeteners and emulsifier polysorbate-80 (P-80) in patients with CD and assess their associations with disease activity. DESIGN: 1461 biosamples from 487 subjects (245 CD and 242 controls) across Australia, Hong Kong and Chinese Mainland were analysed for aspartame, sucralose, saccharin and P-80 levels in stool, urine and serum. CD activity was assessed using Crohn's Disease Activity Index and faecal calprotectin. A generalised linear model (GLM) with P-80 and sweeteners distinguished active CD from inactive CD. RESULTS: Patients with CD had higher sweetener levels compared with controls across cohorts (all p<0.0001). P-80 underwent predominantly hydrolytic and oxidoreductive degradation in CD and controls, respectively, while its native form was undetectable. CD-associated P-80 metabolites positively correlated with urinary sweeteners in patients with CD. In vitro, CD-associated P-80 metabolites increased gut permeability, enabling translocation of sweeteners across the epithelium. Sweeteners and specific CD-associated P-80 metabolites were higher in active CD. The GLM built using sweeteners and P-80 metabolites distinguished active CD from inactive CD, achieving an area under the curve (AUC) of 0.86 in the discovery cohort and average AUC of 0.94 in two independent validation cohorts from Australia and Chinese Mainland. CONCLUSION: This is the first human study to demonstrate distinct P-80 metabolism in patients with CD compared with controls. Dietary sweeteners and P-80 metabolites showed significant correlations with disease activity, suggesting their potential utility as non-invasive biomarkers for CD activity assessment.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhang J, Hu J, Tang X, et al. Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach. Gut. 2026. PMID: 41951359. doi:10.1136/gutjnl-2024-333999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。